Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Conferences

Conference Coverage

Conference Listing

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

Alopecia profoundly disrupts identity, emotional wellbeing, and social life, with many people struggling due to stigma, concealment pressures, and unmet psychological support needs.

Exploring Identity, Appearance Experiences Among Patients With Alopecia

Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist.

5 Things to Know About the Oral GLP-1 Era

Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (

®). She joined AJMC® in 2013 and is the primary staff editor for 

the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for 

®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for 

Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on 

A study from Sweden, the largest of its kind, challenges the standard 24-month milestone as the key point when early relapse is a concern.

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma

Study links elevated serum haptoglobin to chronic spontaneous urticaria activity, suggesting it predicts treatment response and complete disease control.

Potential Predictor of Treatment Response in Chronic Spontaneous Urticaria Identified

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1rem

Compendium

Experts raise concerns that CDC childhood immunization changes could reduce vaccine uptake and weaken trust in public health guidance.

Experts Warn That CDC Childhood Immunization Schedule Revisions Could Reduce Uptake, Erode Public Trust

Almost half of the monthly-updated CDC databases had unexplained pauses in 2025, mostly affecting vaccination data, raising transparency and public health concerns.

Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns

New research highlights the effectiveness of RSV preF vaccines in preventing severe respiratory infections in older adults.

Meta-Analysis Supports RSV Vaccine Efficacy and Safety in Older Adults 

Respiratory syncytial virus (RSV) remains a leading cause of acute bronchitis in children, but new research may enable earlier intervention.

Potential Biomarkers of RSV Bronchiolitis Severity Identified

Our top RSV content of 2025 included how nirsevimab and clesrovimab changed RSV prevention among younger patients, as well as the positive impact of RSV vaccination in older individuals.

Videos

Joseph Aracri, DO, from Allegheny Health Network discussed how parents can help treat their child should they get respiratory syncytial virus (RSV) and how severe this season will be.

Dr Joseph Aracri Discusses Severity, Protection for Coming RSV Season

Joseph Aracri, DO, system chair of pediatrics with AHN Pediatric Institute  and medical director of the Medical Nutrition Clinic, Allegheny Health Network, spoke with 

 about preventing respiratory syncytial virus (RSV) in infants and young children.

How are new vaccines changing treatment of RSV in infants and young children?

The treatment for children, for infants, is not a vaccine, it's an immunoglobulin. So what we're doing is actually giving antibodies to the babies when they're born to help prevent significant RSV disease. That is, RSV disease that will end up in the hospital or frequent visits to the pediatrician's office. We really think that this is going to be a

for these kids and hopefully keep them well through their first respiratory season.

What are some other things that parents can do to protect their children from severe infection?

Really, RSV is a very contagious virus that goes around every year. Usually, by the time the kid is 2, they've already had 2 infections. The majority of RSV infections are just runny nose, cough, maybe a low-grade fever. In some kids, fewer than 5%, [they] will have trouble breathing and almost like an asthma-like attack that's associated with it. What can you do to prevent it? It's just basically other things you do to prevent colds. You know, making sure you wash your hands before touching your baby. If somebody is sick, don't have them around your baby. Those kinds of things. But really, the virus is so contagious and all over the place, it's very hard to avoid.

Joseph Aracri, DO, Allegheny Health Network, spoke with The American Journal of Managed Care® about preventing respiratory syncytial virus (RSV) through immunoglobulin-based treatments and everyday actions.

Providers

Dr Joseph Aracri Discusses RSV in Infants

The panel concludes its discussion by providing key takeaways on the evolving RSV vaccination landscape.

Key Takeaways on RSV Vaccination

Video content above is prompted by the following question:

What are your key takeaways pertaining to RSV vaccination practices?

Experts on RSV provide insights on improving RSV vaccination rates, highlighting ways to navigate misinformation.

Improving RSV Vaccination Rates and Addressing Misinformation

Video content above is prompted by the following questions:

How do you avoid any missed chances to vaccinate against RSV?

How do you address misinformation out there about RSV with patients?


The panel discusses what’s needed for payers to activate early coverage for RSV vaccines in adults and how coverage has been since the approval of the 2 RSV vaccines.

Improving Insurance Coverage for RSV Vaccines

With RSV season shifting earlier in the year and hospitalization rates increasing, what is needed for payers to activate early coverage for RSV vaccines in adults?

How has the recommendation from the ACIP (Advisory Committee on Immunization Practices) impacted coverage of an RSV vaccine?

How has coverage by insurance companies been since the approval (60+) of the 2 RSV vaccines?

How can potential insurance coverage for RSV vaccines for those between 50-59 be optimized?


An internal medicine pharmacist discusses current and potential obstacles related to administering RSV vaccines to patients from different age groups.

Current and Potential Obstacles Related to Administering RSV Vaccines

What have the potential obstacles related to administering RSV vaccines been since approval for patients aged 60+?

What obstacles do you foresee for patients between 50-59?

Experts from clinical and payer backgrounds discuss how patients eligible for the RSV vaccine can be identified.

Identifying Patients Eligible for RSV Vaccine

How have eligible patients for the RSV vaccine been identified in pharmacies and health systems? Have RSV vaccines become annual immunizations like flu vaccines?

Have electronic health records been built to identify eligible patients and incorporate RSV vaccines immunization records? How has the identification of eligible patients been implemented into workflow?

From a payer perspective, how have you ensured eligible patients are identified for immunization?


Mary Bridgeman, PharmD, BCPS, BCGP, discusses how providers and healthcare workers can address vaccine fatigue in patients eligible for the RSV vaccine.

Addressing Vaccine Fatigue

How can providers and healthcare workers address vaccine fatigue in eligible patients?

As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits.

The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59

What is the important phase 3 data for the RSV vaccine that is leading the FDA to consider an expanded age range to 50-59?

How would RSV vaccine approval for adults aged 50-59 improve the clinical and economic impact of the disease?

What will the best practices be for identifying patients who are eligible for receiving the RSV vaccine with the potential updated indication?

How should payers adjust coverage decisions for RSV vaccines in patients aged 50-59 if this expanded indication is approved?

How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?


Following the recent approval of RSV vaccines, the panel discusses the financial and clinical benefits, highlighting the fiscal impact seen in hospitals and ICUs.

Financial and Clinical Benefits of RSV Immunization

With RSV vaccines newly approved, what are the financial and clinical goals associated with immunizing against RSV?

Have payers activated early coverage for the adult RSV vaccines since they entered to reduce costs?

How have RSV vaccines altered the fiscal impact associated with managing RSV infections in hospitals or ICUs?


Experts on RSV vaccination discuss shared decision-making practices and the importance of getting at-risk patients vaccinated.

Shared Decision-Making Practices in RSV

How do you utilize shared decision-making when deciding whether to vaccinate patients for RSV?

The expert panel discusses ways to increase awareness of the RSV vaccine for patients who would benefit from it.

Increasing Awareness of RSV Vaccines in At-Risk Patients

With adult RSV vaccines recently approved, how can healthcare providers increase awareness for at-risk populations and educate on infection prevention strategies?

How has limited public awareness of adults at risk for RSV infections impacted clinical practice?


RSV

Latest News